BLI-1008

SILICON VALLEY, CA – June 26, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, proudly announces that a podcast with Biotech Orbit (https://youtu.be/TYrNEA0mG-8?si=xnCCjK1ZrRIw8OK7), featured the Company’s Chief Executive Officer, Dr. Uttam Patil, among their list of the most influential Indian-origin CEOs leading major global organizations. On the podcast, Dr. Patil discussed the Company’s flagship antidepressant candidate, ABV-1504, which is preparing to enter Phase III clinical trials. In the interview, Dr. Patil emphasized a critical differentiator found thus far in in-house trials of ABV-1504 – the absence of suicidal ideation, a side effect commonly associated with conventional synthetic antidepressants. “We believe ABV-1504 represents the potential for a new generation of safe, plant-derived psychiatric treatments,” said Dr. Patil. He continued, “While the medical community remains cautious toward botanical drugs, we are hopeful that our clinical program will build the confidence needed to drive acceptance and adoption globally.” Dr. Patil joins an exclusive group of Indian-origin CEOs leading major global institutions. His inclusion on the list underscores the rising influence of biotech executives with deep R&D roots and global strategic vision. Under his leadership, ABVC BioPharma has built a differentiated botanical drug platform supported by rigorous science and clinical evidence. The upcoming Phase III study of ABV-1504 aims to position the drug as the world’s first botanical antidepressant with no suicide-related side effects, which would mark a potential paradigm shift in the treatment of Major Depressive Disorder (MDD). ABVC BioPharma is strategically positioned in growing markets. The global MDD market is projected to grow from $11.51 billion in 2022 to $14.96 billion by 2032, with a steady CAGR of 2.8%.[1] The global ADHD treatment market is also growing, expected to increase from $15.23 billion in 2022 at a CAGR of 7.3% through 2032.[2] Additionally, the global botanical drug market, valued at $163 million in 2021, is forecasted to experience an impressive CAGR of 39% through 2030, reaching $3.2 billion.[3] About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II/III of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact:Uttam PatilEmail: uttam@ambrivis.com [1] https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%20major%20depressive%20disorder%20(MDD,US%24%2011.51%20billion%20in%202022 [2] https://www.polarismarketresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-market [3] https://straitsresearch.com/report/botanical-drugs-market